32: Drug Action on Dopamine Receptors Flashcards

1
Q

Explain the mechanism of dopamine after signaling in/across the synaptic cleft.

A
  • A part of dopamine crosses the synaptic cleft and binds to dopamine receptors in the postsynaptic membrane.
  • After activation of the receptors, the dopamine receptors drive a series of downstream signaling for physiological functions.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the two types of dopamine receptors?

A

D1-like receptors (D1, D5)
D2-like receptors (D2, D3, D4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Explain the result of dopamine receptor activation on adenylyl cyclase.

A

D1-like receptors - when dopamine binds –> AC is activated (more cAMP)
D2-like receptors - when dopamine binds –> AC is inhibited (less cAMP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain the results of dopamine activation of D1-D1, D2-D2, and D1-D2 receptors.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In the brain, what are the pathways that dopamine contributes to?

A

mesocortical
mesolimbic
nigrostriatal
tuberoinfundibular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Name which human diseases are associated with decreased dopamine receptors.

A
  • parkinson’s disease
  • hyperprolactinemia
  • restless leg syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Name the two types of dopamine receptor agonists.

A

Ergoline type
Non-ergoline type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the role of dopamine in parkinson’s disease development.

A

Dopamine neurons in the brain slowly break down and can eventually die.
* With decreasing levels of dopamine, the brain can’t function properly –> abnormal brain activity –> parkinson’s symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the two fundamental ways to treat parkinson’s disease.

A
  • replace dopamine
  • mimick dopamine’s effect (using dopamine agonists)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe characteristics of patients with parkinson’s disease.

A
  • depressive symptoms/disorders are common
  • **increased anxiety **–> accentuate symptoms of the disease
  • treatment of non-ergoline agonists have been suggested - D2-like agonists.
  • not ergoline agonists –> bc of risk of cartilage formation in heart valves.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the association between dopamine and hyperprolactinemia.

A

Hyperprolactinemia is the presence of abnormally high levels of prolactin in blood.
* dopamine is a prolactin-inhibiting factor –> lowers prolactin-releasing factors synthesis and secretion through D2-like receptors.
* Treatment: ergoline-derived agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the association between dopamine and restless leg syndrome.

A

RLS is a long-term disorder that causes strong urge to move one’s leg with unpleasant feeling.
* dopamine-dependent disorder
* stimulation of dopamine receptors –> increase dopamine levels –> decrease RLS symptoms
* treatment: non-ergoline agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the human diseases that are associated with increased dopamine functions.

A
  • schizophrenia
  • bipolar disorder
  • huntington’s disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name the two types of dopamine receptor antagonists.

A
  • first generation antipsychotics (more adverse reactions, cheaper)
  • second generation antipsychotics (less adverse reactions, more expensive)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the association between dopamine and schizophrenia.

A

Alterations of dopamine receptors and abnormalities in glutamatergic signaling are involved in the genesis of psychotic and cognitive symptoms.
* treatment: second generation antipsychotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the association between dopamine and bipolar disorder.

A

AKA manic depression - extreme mood swings that include extreme highs and lows.
* treatment: mood stabilizers, antipsychotics, antidepressants, antipsychotics-antidepressants, antianxiety medications

17
Q

Describe the association between dopamine and huntington’s disease.

A

Huntington’s disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain.
* unusually high levels of dopamine –> cause chorea (involuntary jerking or writhing movements)
* treatment: drugs to control movement and antipsychotics

18
Q

Cabergoline
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor agonist - ergoline type
Target protein: D2-like receptors
Therapeutic indication: hyperprolactinemia

19
Q

Bromocriptine
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor agonist - ergoline type
Target protein: D2-like receptors
Therapeutic indication: hyperprolactinemia

20
Q

Pramipexole
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor agonist - non-ergoline type
Target protein: D2-like receptors
Therapeutic indication: Parkinson’s disease & restless leg syndrome

21
Q

Rotigotine
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor agonist - non-ergoline type
Target protein: D2-like receptors
Therapeutic indication: parkinson’s disease & restless leg syndrome

22
Q

Fluphenazine
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor antagonist - first gen
Target protein: D2-like receptors
Therapeutic indication: Huntington’s disease

23
Q

Risperidone
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine-receptor antagonist - second gen
Target protein: D2-like receptors
Therapeutic indication: Schizophrenia & bipolar disorder

24
Q

Olanzapine
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor antagonist - second gen
Target protein: D2-like receptors
Therapeutic indication: schizophrenia & bipolar disorder

25
Q

Haloperidol
Drug action:
Target protein:
Therapeutic indication:

A

Drug action: dopamine receptor antagonist - second gen
Target protein: D2-like receptors
Therapeutic indication: schizophrenia & bipolar disorder & huntington’s disease

26
Q
A

C. D1-D2 heterodimer

27
Q
A

C. Heart

28
Q
A

E. A and D

29
Q
A

B. agonists of dopamine receptors

30
Q
A

A. Bromocriptine